311 related articles for article (PubMed ID: 36430263)
21. The value of adjuvant chemotherapy in the management of sarcomas in children.
Donaldson SS
Cancer; 1985 May; 55(9 Suppl):2184-97. PubMed ID: 3884137
[TBL] [Abstract][Full Text] [Related]
22. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
Shor AC; Keschman EA; Lee FY; Muro-Cacho C; Letson GD; Trent JC; Pledger WJ; Jove R
Cancer Res; 2007 Mar; 67(6):2800-8. PubMed ID: 17363602
[TBL] [Abstract][Full Text] [Related]
23. Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas.
Nakano K; Takahashi S
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29510588
[TBL] [Abstract][Full Text] [Related]
24. Challenges of Systemic Therapy Investigations for Bone Sarcomas.
Nakano K
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408900
[TBL] [Abstract][Full Text] [Related]
25. Use of chemotherapy for patients with bone and soft-tissue sarcomas.
Wesolowski R; Budd GT
Cleve Clin J Med; 2010 Mar; 77 Suppl 1():S23-6. PubMed ID: 20179184
[TBL] [Abstract][Full Text] [Related]
26. Homogenous and Heterogenous Prognostic Factors for Patients with Bone Sarcoma.
Xu G; Wu H; Xu Y; Zhang Y; Lin F; Baklaushev VP; Chekhonin VP; Peltzer K; Wang X; Mao M; Wang G; Cui P; Zhang C
Orthop Surg; 2021 Feb; 13(1):134-144. PubMed ID: 33305494
[TBL] [Abstract][Full Text] [Related]
27. Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial.
Xie L; Xu J; Sun X; Tang X; Yan T; Yang R; Guo W
Oncologist; 2019 Jul; 24(7):e542-e550. PubMed ID: 30559126
[TBL] [Abstract][Full Text] [Related]
28. Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa.
Assi A; Farhat M; Hachem MCR; Zalaquett Z; Aoun M; Daher M; Sebaaly A; Kourie HR
J Bone Oncol; 2023 Dec; 43():100511. PubMed ID: 38058514
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas.
Shor AC; Agresta SV; D'Amato GZ; Sondak VK
Cancer Control; 2008 Jan; 15(1):47-54. PubMed ID: 18094660
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy for Bone Sarcoma in Adults.
Wagner MJ; Livingston JA; Patel SR; Benjamin RS
J Oncol Pract; 2016 Mar; 12(3):208-16. PubMed ID: 26962160
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.
Fox E; Patel S; Wathen JK; Schuetze S; Chawla S; Harmon D; Reinke D; Chugh R; Benjamin RS; Helman LJ
Oncologist; 2012; 17(3):321. PubMed ID: 22363068
[TBL] [Abstract][Full Text] [Related]
32. Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma.
Canter RJ; Ames E; Mac S; Grossenbacher SK; Chen M; Li CS; Borys D; Smith RC; Tellez J; Sayers TJ; Monjazeb AM; Murphy WJ
BMC Cancer; 2014 Oct; 14():756. PubMed ID: 25301268
[TBL] [Abstract][Full Text] [Related]
33. Phase 1 clinical trials for sarcomas: the cutting edge.
Subbiah V; Kurzrock R
Curr Opin Oncol; 2011 Jul; 23(4):352-60. PubMed ID: 21519259
[TBL] [Abstract][Full Text] [Related]
34. Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines.
Duan Z; Choy E; Harmon D; Yang C; Ryu K; Schwab J; Mankin H; Hornicek FJ
Mol Cancer Ther; 2009 Aug; 8(8):2122-30. PubMed ID: 19638450
[TBL] [Abstract][Full Text] [Related]
35. Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.
Shaikh AB; Li F; Li M; He B; He X; Chen G; Guo B; Li D; Jiang F; Dang L; Zheng S; Liang C; Liu J; Lu C; Liu B; Lu J; Wang L; Lu A; Zhang G
Int J Mol Sci; 2016 Apr; 17(4):506. PubMed ID: 27058531
[TBL] [Abstract][Full Text] [Related]
36. Hedgehog pathway in sarcoma: from preclinical mechanism to clinical application.
Banaszek N; Kurpiewska D; Kozak K; Rutkowski P; Sobczuk P
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17635-17649. PubMed ID: 37815662
[TBL] [Abstract][Full Text] [Related]
37. Role of TKI for Metastatic Osteogenic Sarcoma.
Duffaud F
Curr Treat Options Oncol; 2020 Jun; 21(8):65. PubMed ID: 32601895
[TBL] [Abstract][Full Text] [Related]
38. Targeting sarcomas: therapeutic targets and their rational.
Ordóñez JL; Martins AS; Osuna D; Madoz-Gúrpide J; de Alava E
Semin Diagn Pathol; 2008 Nov; 25(4):304-16. PubMed ID: 19013896
[TBL] [Abstract][Full Text] [Related]
39. Bisphosphonates in common pediatric and adult bone sarcomas.
Heymann MF; Lezot F; Heymann D
Bone; 2020 Oct; 139():115523. PubMed ID: 32622877
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy in the management of osteosarcoma and Ewing's sarcoma.
Schuetze SM
J Natl Compr Canc Netw; 2007 Apr; 5(4):449-55. PubMed ID: 17442235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
